Epigral Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kiok7ov7p0luscvf1ojmc855.pdf

Key Takeaways


Chlorine Integration & the ECU Hedge

Maulik Patel: "once it reached at optimum level, we are 90% going to be a internal and captive consumption going forward and the pipeline customers are hardly it is 20% maximum right now, and that is going to be remain constant."

Derivatives & Specialty: The Mix Shift in Motion


Growth Roadmap: Capacity, Capex & New Chemistry

Maulik Patel: "We are not going to enter in the similar chlor-alkali that... we are looking for a couple of chemistry which we are planning to do it based on the India growth story on the next 10 years."

Margins: Normalisation, Not Erosion

Milind Kotecha: "Even at 28% is something which is, is good number. And considering the guidance that we had given, it was around 25%. So it's not a drop of by 2% in fact, 28% itself is more like a realistic number rather than 30%."

Market Context: Caustic Firm, Chlorine Weak

Maulik Patel: "caustic soda price are remaining soft globally, the reason behind is the downstream chemistry which is used chlorine globally, which is almost 60% to 65% that is very low... we are thinking that the caustic soda will remain firm even current this financial year, as well as going forward also."

Guidance & Commitments

CommitmentSpecificsTimeline
Chlorotoluene ramp-upReach optimal utilisationBy Q4 FY26 (Dec/Jan timeframe)
Derivatives & Specialty revenue shareReach ~70% of total revenueOnce chlorotoluene, CPVC resin, and ECH expansions reach optimal utilisation
Captive chlorine consumptionReach 80-85%By FY27, when ECH and CPVC expanded capacities come on stream
Epichlorohydrin capacity expansionDouble to 1,00,000 tonnesFirst half of FY27
CPVC resin capacity expansionDouble to 1,50,000 tonnesTimeline not specified; announced in Q4 FY25
FY26 capex~₹450 croreFY26
Volume growth10-15% CAGRNext five years
Long-term EBITDA margin25% achievableLonger-term basis
Caustic soda efficiency improvementBenefit from membrane and electrolyser replacementFrom Q1 FY26 onwards

Key Metrics

MetricQ4 FY25
Revenue₹631 crore, +20% YoY vs ₹526 crore in Q4 FY24
EBITDA₹173 crore, +12% YoY vs ₹155 crore in Q4 FY24
PAT₹87 crore, +13% YoY vs ₹77 crore in Q4 FY24; margin at 14%
FY25 revenue₹2,565 crore, highest ever, +33% vs FY24
FY25 PAT₹357 crore, highest ever, +82% vs ₹196 crore in FY24
FY25 EBITDA₹711 crore, +48% YoY; EBITDA margin 28% vs 25% in FY24
FY25 capacity utilization81% vs 78% in FY24
FY25 ROCE25% including CWIP vs 17% in FY24; 28% excluding CWIP
Net debt-to-EBITDA0.7x at end March 2025 vs 2.0x at end March 2024
Derivatives & Specialty revenue contribution54% in FY25 vs 45% in FY24
Captive chlorine consumption72% in FY25
ECU realization~₹33,000, chlorine at ~negative ₹5,000
FY26 CAPEX plan~₹450 crore
FY26 volume growth guidance10% to 15% driven by CPVC, ECH ramp-up and chlorotoluene contribution
CRISIL ratingUpgraded to CRISIL AA Stable from CRISIL AA- positive outlook